6667 Stock Overview
A genetic testing platform company, provides consumer genetic testing and cancer screening services in China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Mega Genomics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$10.60 |
| 52 Week High | HK$12.40 |
| 52 Week Low | HK$7.68 |
| Beta | 0 |
| 1 Month Change | -0.75% |
| 3 Month Change | 15.22% |
| 1 Year Change | 5.58% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -41.11% |
Recent News & Updates
Recent updates
Some Investors May Be Worried About Mega Genomics' (HKG:6667) Returns On Capital
May 03
Calculating The Intrinsic Value Of Mega Genomics Limited (HKG:6667)
Feb 20Mega Genomics Limited's (HKG:6667) Share Price Could Signal Some Risk
Aug 12A Look At The Fair Value Of Mega Genomics Limited (HKG:6667)
Nov 07Shareholder Returns
| 6667 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | 14.3% | -1.2% | -2.3% |
| 1Y | 5.6% | -22.7% | 0.3% |
Return vs Industry: 6667 exceeded the Hong Kong Healthcare industry which returned -22.7% over the past year.
Return vs Market: 6667 exceeded the Hong Kong Market which returned 0.3% over the past year.
Price Volatility
| 6667 volatility | |
|---|---|
| 6667 Average Weekly Movement | 9.9% |
| Healthcare Industry Average Movement | 6.1% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in HK Market | 15.7% |
| 10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 6667 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6667's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 229 | n/a | www.megagenomics.cn |
Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing and cancer screening services in China. It offers general testing services, including brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; and cardiovascular and cerebrovascular disease risk assessment packages. The company also provides advanced testing services, such as hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; RNF180/Septin9 gastric cancer screening test; and telomere length genetic testing that assesses the cell age and aging rate of a person.
Mega Genomics Limited Fundamentals Summary
| 6667 fundamental statistics | |
|---|---|
| Market cap | HK$2.51b |
| Earnings (TTM) | HK$32.44m |
| Revenue (TTM) | HK$163.39m |
77.3x
P/E Ratio15.3x
P/S RatioIs 6667 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6667 income statement (TTM) | |
|---|---|
| Revenue | CN¥151.30m |
| Cost of Revenue | CN¥63.00m |
| Gross Profit | CN¥88.30m |
| Other Expenses | CN¥58.26m |
| Earnings | CN¥30.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 58.36% |
| Net Profit Margin | 19.85% |
| Debt/Equity Ratio | 3.5% |
How did 6667 perform over the long term?
See historical performance and comparison